The use of low molecular weight heparin (LMWH) for the prevention and treatment of venous thromboembolism has been validated by numerous clinical trials and meta-analyses over the past 25 years. More recently, the possibility of extending treatment with LMWH to the arterial disease where thrombosis is a prominent feature has led to the planning of many clinical trials, several of which have been already published. LMWH has been tested in settings such as acute coronary syndromes, including myocardial infarction, surgery or percutaneous revascularization for coronary and peripheral arteries, and stroke. In most indications, LMWH has proved to be superior to or at least as effective as unfractionated heparin and it is also easier to administer.
Agnelli G, Iorio A, Renga Cet al.Prolonged antithrombin activity of low-molecular-weight heparins: clinical implications for the treatment of thromboembolic diseases. Circulation1995; 92: 2819-2824.
2.
Glick A, Kornowski R, Michowic Yet al.Reduction of reinfarction and angina with use of low-molecular weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Am J Cardiol1996; 77: 1145-1148.
3.
Frostfeldt G, Ahlberg G, Gustafsson Get al.Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction - a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). J Am Coll Cardiol1999; 33: 627-633.
4.
Kontny F, Dale J, Abildgaard U, Pedersen TR.Randomised trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol1997; 30: 962-969.
5.
Gurfinkel EP, Manos EJ, Mejail RIet al.Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol1995; 26: 313-318.
6.
The Fraxis Study Group. Comparison of two treatment duration (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction. FRAX.I.S. (FRAXiparine in Ischaemic Syndrome). Eur Heart J1999; 20: 1553-1562.
7.
Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet1996; 347: 561-568.
8.
Klein W, Buchwald A, Hillis WSet al.Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation1997; 96: 61-68.
9.
Fragmin and Fast Revascularisation during Instability in Coronary artery disease (FRISC II) Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet1999; 354: 701-707.
10.
Fragmin and Fast Revascularisation during Instability in Coronary artery disease (FRISC II) Investigators. Invasive compared with noninvasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet1999; 354: 708-715.
11.
Cohen M, Demers C, Gurfinkel EPet al for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med1997; 337: 447-452.
12.
Antman EM, McCabe CH, Gurfinkel EPet al.Enoxaparin prevents death and cardiac ischaemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation1999; 100: 1593-1601.
13.
Noble S, Spencer CM.Enoxaparin. A review of its clinical potential in the management of coronary artery disease. Drugs1998; 56: 259-272.
14.
Mark DB, Cowper PA, Berkowitz SDet al.Economic assessment of low-molecular-weight heparin (Enoxaparin) versus unfractionated heparin in acute coronary syndrome patients. Results from the ESSENCE randomized trial. Circulation1998; 97: 1702-1707.
15.
Fox KAA, Bosanquet N.Assessing the UK cost implication of the use of low molecular weight heparin in unstable coronary artery disease. Am J Cardiol1998; 5: 92-105.
16.
Cohen M, Biganzi F, Le Iouer W, Goffet F, Fromell GJ, Goodman S.One-year follow-up of the ESSENCE trial. J Am Coll Cardiol1998; 31 (suppl A): 79-A.
17.
Antman EM, Cohen M, Radley Det al.Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation1999; 100: 1602-1608.
18.
Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S.Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet2000; 355: 1936-1942.
Karsch KR, Preisack MB, Baildon Ret al.Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of restenosis after PTCA, early administration of reviparin in a double-blind unfractionated heparin and placebo-controlled evaluation. JAm Coll Cardiol1996; 28: 1437-1443.
21.
Faxon DP, Spiro TE, Minor Set al.Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial. Circulation1994; 90: 908-914.
22.
Lablanche JM, McFadden EP, Meneveau Net al.Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Circulation1997; 96: 3396-3402.
23.
Brack MJ, Ray S, Chauhan Aet al.The Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) trial. Results of a multi-center randomized trial investigating the effects of high-dose unfractionated heparin on angiographic restenosis and clinical outcome. J Am Coll Cardiol1995; 26: 947-954.
24.
Zidar JP.Low-molecular-weight heparins in coronary stenting (the ENTICES trial). Enoxaparin and Ticlopidine after Elective Stenting. Am J Cardiol1998; 82: 29-32.
25.
Tcheng J.Practical application for low molecular weight heparins in acute and chronic coronary syndromes: insights from ATLAST, ESSENCE, TIMI-11B and beyond. Eleventh Transcatheter Cardiovascular Therapeutics conference, Washington, 1999.
26.
Rabah MM, Premmereur J, Graham Met al.Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol1999; 84: 1391-1395.
27.
Edmonson RA, Cohen AT, Das SK, Wagner MB, Kakkar VV.Low molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet1994; 344: 914-918.
28.
Strecker EP, Gottman D, Boos IB, Vetter S.Low molecular weight heparin (reviparin) reduces the incidence of femoropopliteal in-stent stenosis: preliminary results of an ongoing study. Cardiovasc Intervent Radiol1998; 21: 375-379.
29.
Samama CM, Gigou F, Ill P.Low molecular weight heparin vs unfractionated heparin in femorodistal reconstructive surgery: a multicenter open randomized study. Enoxart Study Group. Ann Vasc Surg1995; 9 (suppl): S45-S53.
30.
Swedenborg J, Nydahl S, Egberg N.Low molecular mass heparin instead of unfractionated heparin during infrainguinal bypass surgery. Eur J Vasc Endovasc Surg1996; 11: 59-64.
31.
International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997; 349: 1569-1581.
32.
Kay R, Wong KS, Yu YLet al.Low molecular weight heparin for the treatment of acute ischaemic stroke. N Engl J Med1995; 333: 1588-1593.
33.
The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischaemic stroke. A randomized controlled trial. JAMA1998; 279: 1265-1272.
34.
Berge E, Abdelnoor M, Nakstad PH, Sandset PM, on behalf of the HAEST Study Group. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. Lancet2000; 355: 1205-1210.
35.
Furberg CD.Natural statins and stroke risk. Circulation1999; 99: 185-188.
36.
Nenci GG.Concluding the clinical survey on LMWHs. In: Janet M, Kher A, Toulemonde F (eds). Low molecular weight heparins therapy. New York, Basel: Marcel Dekker, 1999: 464-465.
37.
Turpie AGG.Can we differentiate the low-molecular-weight heparins?Clin Cardiol2000; 23 (suppl I): I-4-I-7.
38.
Cruickshank MK, Levine MN, Hirsh Jet al.A standard heparin nomo-gram for the management of heparin therapy. Arch Intern Med1991; 151: 333-337.
39.
de Bono DP, Simoons ML, Tijssen Jet al.Effect of early intravenous heparin on coronary patency, infarct size and bleeding complication after alteplase thrombolysis: results of a randomised double-blind European Cooperative Study Group Trial. Br Heart J1992; 67: 122-128.
40.
Baker BA, Adelman MD, Smith PAet al.Inability of the activated partial thromboplastin time to predict heparin levels. Arch Intern Med1997; 157: 2475-2479.
41.
Young E, Wells P, Holloway Set al.Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma protein than unfractionated heparin. Thromb Haemost1994; 71: 300-304.
